Potent, selective and cell-permeable c-Raf1 kinase inhibitor (IC50
= 9 nM). Displays ≥ 100-fold selectivity for raf kinase over CDK1, CDK2, c-src, ERK2, MEK, p38, Tie2, VEGFR2 and c-fm.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Sold for research purposes under agreement from Glaxo Wellcome Inc and Glaxo Group Ltd.
Inhibition of ATF-3 expression by B-Raf mediates the neuroprotective action of GW5074.
Chen et al.
VEGF increases endothelial permeability by separate signaling pathways involving ERK-1/2 and nitric oxide.
Breslin et al.
Am.J.Physiol.Heart Circ.Physiol., 2003;284:H92
The discovery of potent cRaf1 kinase inhibitors.
Lackey et al.
Involvement of Raf-1 in chronic delta-opioid receptor agonist-mediated adenylyl cyclase superactivation.
Varga et al.
The citations listed below are publications that use Tocris products. Selected citations for GW 5074 include:
Showing Results 1 - 7 of 7